Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | CCR10 | P46092 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8478713 | 0.97 | LMNA (0.51) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131569 | 0.96 | LMNA (0.55) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL8473394 | 0.94 | LMNA (0.55) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131605 | 0.89 | CA12 (0.46) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131582 | 0.88 | LMNA (0.49) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131586 | 0.87 | LMNA (0.47) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131583 | 0.87 | LMNA (0.47) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131543 | 0.86 | LMNA (0.47) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131633 | 0.86 | LMNA (0.47) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6131613 | 0.86 | LMNA (0.47) | LMNATHRBCYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | claimed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | claimed |
| US-6184361-B1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2001-02-06 | — | — | US | claimed |
| US-5808091-A | DIAGNOSTIC IMAGING AGENT | BRACCO INTERNATIONAL B.V. | 1998-09-15 | — | — | US | claimed |
| US-5688487-A | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1997-11-18 | — | — | US | claimed |
| CN-1093084-A | The rhenium and the technetium complex that comprise the anoxic localization part | SQUIBB & SONS INC (US) | 1994-10-05 | — | — | CN | claimed |
| CN-1071928-A | The rhenium and the technetium complex that comprise the anoxic localization part | SQUIBB & SONS INC (US) | 1993-05-12 | — | — | CN | claimed |
| JP-5239046-A | — | — | None | — | — | JP | disclosed |
| US-6958141-B2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2005-10-25 | — | — | US | disclosed |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2004-09-30 | — | — | US | disclosed |
| US-6699458-B2 | CELL MEMBRANE PERMEABILITIES GREATER THAN THAT OF SUCROSE | BRACCO INTERNATIONAL B.V. (NL) | 2004-03-02 | — | — | US | disclosed |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | disclosed |
| EP-0544412-B1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INT BV (NL) | 1997-07-23 | — | — | EP | disclosed |
| EP-0712315-A1 | RADIOMETAL COMPLEXES THAT LOCALISE IN HYPOXIC TISSUE | AMERSHAM INTERNATIONAL plc (GB) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004552-A2 | RADIOMETAL COMPLEXES THAT LOCALISE IN HYPOXIC TISSUE | AMERSHAM INTERNATIONAL PLC (GB) | 1995-02-16 | — | — | WO | disclosed |
| CN-1093084-A | The rhenium and the technetium complex that comprise the anoxic localization part | SQUIBB & SONS INC (US) | 1994-10-05 | — | — | CN | disclosed |
| JP-H05239046-A | RHENIUM AND TECHNETIUM COMPLEX CONTAINING HYPOXIA LOCALITY RESIDUE | E R SQUIBB & SONS INC | 1993-09-17 | — | — | JP | disclosed |
| EP-0544412-A2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1993-06-02 | — | — | EP | disclosed |
| CN-1071928-A | The rhenium and the technetium complex that comprise the anoxic localization part | SQUIBB & SONS INC (US) | 1993-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | LMNA 4114/4885THRB 618/4885CYP2C19 4764/4885 |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | LMNA 4114/4885THRB 618/4885CYP2C19 4764/4885 |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | LMNA 4114/4885THRB 618/4885CYP2C19 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.